Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Pilot Study of Mesenchymal Stem Cells as Novel Therapy for Age-Related Frailty in Veterans
Authors not listed
VA Office of Research and Development · 2023
Abstract
Frailty is a health state related to the aging process in which multiple body systems gradually lose their built-in reserves. It is a medical condition of reduced function in older adults which is associated with increased risks of adverse outcomes such as falls, disability, admission to hospital, or need for long-term care. Currently, there is no specific medical treatment of frailty. Mesenchymal stem cells (MSCs) are undifferentiated cells that self-replicated, and some may change into a particular cell type. These cells go to areas of injury due to signals released by injured cells. Upon reaching, the target tissue, MSCs repair injury by releasing growth factors and immune modulators to assist in the body's repair process. This initial study will assess the practicability of using MSCs for age-related frailty and provide information for planning a future full study of MSCs for maximizing Veteran's functional independence.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-24 MST
Cite this
APA
Anonymous. (2023). A Pilot Study of Mesenchymal Stem Cells as Novel Therapy for Age-Related Frailty in Veterans. <em>VA Office of Research and Development</em>. https://clinicaltrials.gov/study/NCT05284604
Vancouver
Anonymous. A Pilot Study of Mesenchymal Stem Cells as Novel Therapy for Age-Related Frailty in Veterans. VA Office of Research and Development. 2023.
BibTeX
@misc{anon2023APilot,
title = {A Pilot Study of Mesenchymal Stem Cells as Novel Therapy for Age-Related Frailty in Veterans},
author = {Anonymous},
journal = {VA Office of Research and Development},
year = {2023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The Foundation for Orthopaedics and Regenerative Medicine 2022
Open access · US-GOV
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Aging Frailty
Rejuvenation Research 2019
Open access · CC-BY
Frailty and Rejuvenation with Stem Cells: Therapeutic Opportunities and Clinical Challenges
Longeveron Inc. 2014
Open access · US-GOV
A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty
Mechanisms of Ageing and Development 2019
Citation only
Attenuation of frailty in older adults with mesenchymal stem cells
Theranostics 2021
Open access · CC-BY
Application of mesenchymal stem cell therapy for aging frailty: from mechanisms to therapeutics
Circulation Research 2011
Open access · OA